Description: Vincera Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincera Pharma, Inc. is based in Santa Clara, California.
Home Page: vincerx.com
VINC Technical Analysis
260 Sheridan Avenue
Palo Alto,
CA
94306
United States
Phone:
650 800 6676
Officers
| Name | Title |
|---|---|
| Dr. Ahmed M. Hamdy M.D. | Founder, Chairman & CEO |
| Mr. Tom C. Thomas J.D. | Founder, Gen. Counsel & Chief Legal Officer |
| Dr. Raquel E. Izumi Ph.D. | Founder, Pres, COO, Sec. & Director |
| Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board |
| Mr. Alexander A. Seelenberger M.B.A., MBA | Chief Financial Officer |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer |
| Ms. Melissa Merrick SPHR | Sr. Director of People & Culture |
| Dr. David Nganele M.B.A., Ph.D. | Head of Early Devel. |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Exec. Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2284 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-05-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |